COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022-Reference-Cited by-同舟云学术

COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022

Published:2024-01-21 Issue: Volume: Page:
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Jeantin Lina¹^ORCID,Januel Edouard²^ORCID,Labauge Pierre³,Maillart Elisabeth¹^ORCID,de Seze Jérôme⁴,Zéphir Hélène⁵,Pelletier Jean⁶,Kerschen Philippe⁷,Biotti Damien⁸^ORCID,Heinzlef Olivier⁹,Guilloton Laurent¹⁰,Bensa Caroline¹¹,Théaudin Marie¹²,Vukusic Sandra¹³^ORCID,Casez Olivier¹⁴,Maurousset Aude¹⁵,Laplaud David¹⁶,Berger Eric¹⁷,Lebrun-Frenay Christine¹⁸,Bourre Bertrand¹⁹,Branger Pierre²⁰,Stankoff Bruno²¹,Clavelou Pierre²²,Thouvenot Eric²³^ORCID,Manchon Eric²⁴,Moreau Thibault²⁵,Sellal François²⁶,Zedet Mickaël²⁷,Papeix Caroline¹¹,Louapre Céline¹

Affiliation:

1. Sorbonne University, Paris Brain Institute—ICM, Assistance Publique–Hôpitaux de Paris (AP-HP), Inserm, CNRS, Hôpital de la Pitié Salpêtrière, CIC Neurosciences, FCRIN4MS, Paris, France

2. Sorbonne University, Paris Brain Institute—ICM, Assistance Publique–Hôpitaux de Paris (AP-HP), Inserm, CNRS, Hôpital de la Pitié Salpêtrière, CIC Neurosciences, FCRIN4MS, Paris, France/Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Assistance Publique–Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), Unité de Recherche Clinique PSL-CFX, CIC-1901, Paris, France

3. Department of Neurology, CRC-SEP, Montpellier University Hospital, Montpellier, France/ Institute for Neurosciences of Montpellier (INM), INSERM and University of Montpellier, Montpellier, France

4. Department of Neurology and Clinical Investigation Center, CIC 1434, INSERM 1434, CHU de Strasbourg, Strasbourg, France

5. Department of Neurology, CHU Lille, INSERM U1172, University of Lille, Lille, France

6. Aix-Marseille Universite, APHM, Hôpital de la Timone, Pôle de Neurosciences Cliniques, Service de Neurologie, Marseille, France

7. Department of Neurology, Luxembourg Hospital Center, Luxembourg City, Luxembourg

8. Centre Ressources et Compétences sclérose en plaques (CRC-SEP) et Service de Neurologie B4, Hôpital Pierre-Paul Riquet, CHU Toulouse Purpan, Toulouse, France/ INSERM UMR1291—CNRS UMR5051, Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse 3, Toulouse, France

9. Département de Neurologie, CRC SEP, Centre Hospitalier intercommunal de Poissy-Saint-Germain-en-Laye, Poissy, France

10. Association des Neurologues Libéraux de Langue Française, Rambouillet, France

11. Département de Neurologie, Hôpital Fondation Adolphe de Rothschild, Paris, France

12. Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

13. Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, Bron, France

14. Neurologie, Pathologies Inflammatoires du Système Nerveux, CHU Grenoble Alpes, Grenoble, France/ TIMC-IMAG, Translational Research in Autoimmunity and Inflammation Group (T-RAIG), Université Grenoble Alpes, Grenoble, France

15. CRC SEP and Department of Neurology, CHU de Tours, Hôpital Bretonneau, Tours, France

16. CR2TI UMR1064, Service de Neurologie and CIC0004 INSERM, CHU de Nantes, Nantes, France

17. Service de Neurologie, CHU de Besançon, Besançon, France

18. CRCSEP Cote d’Azur, CHU de Nice Pasteur2, Université Nice Cote d’Azur, UR2CA-URRIS, Nice, France

19. Department of Neurology, CHU Rouen, Rouen, France

20. Service de Neurologie, CHU de Caen Normandie, Caen, France

21. Assistance Publique–Hôpitaux de Paris (AP-HP), Sorbonne Université, Department of Neurology, Saint Antoine Hospital, CRCSEP, Paris, France

22. CRCSEP, Department of Neurology, CHU Clermont-Ferrand, Inserm, Neuro-Dol, Clermont-Ferrand, France

23. Department of Neurology, Nimes University Hospital, Nimes Cedex 9 F-30029, France; Institut de Génomique Fonctionnelle, UMR5203, INSERM 1191, Université de Montpellier, Montpellier, France

24. Department of Neurology, Gonesse Hospital, Gonesse, France

25. EA4184, Department of Neurology, CHU de Dijon, Dijon, France

26. Département de Neurologie, Hôpitaux Civils de Colmar, Colmar, France; Unité INSERM U-1118, Faculté de Médecine, Université de Strasbourg, Strasbourg, France

27. Department of Neurology, AP-HP, Henri Mondor University Hospital, Université Paris Est Créteil, Creteil, France

Abstract

Background: Epidemiologic studies on coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (pwMS) have focused on the first waves of the pandemic until early 2021. Objectives: We aimed to extend these data from the onset of the pandemic to the global coverage by vaccination in summer 2022. Methods: This retrospective, multicenter observational study analyzed COVISEP registry data on reported COVID-19 cases in pwMS between January 2020 and July 2022. Severe COVID-19 was defined as hospitalization or higher severity. Results: Among 2584 pwMS with confirmed/highly suspected COVID-19, severe infection rates declined from 14.6% preomicron wave to 5.7% during omicron wave ( p < 0.001). Multivariate analysis identified age (odds ratio (OR) = 1.43, 95% confidence interval (CI) = [1.25–1.64] per 10 years), male sex (OR = 2.01, 95% CI = [1.51–2.67]), obesity (OR = 2.36, 95% CI = [1.52–3.68]), cardiac comorbidities (OR = 2.36, 95% CI = [1.46–3.83]), higher Expanded Disability Status Scale (EDSS) scores (OR = 2.09, 95% CI = [1.43–3.06] for EDSS 3–5.5 and OR = 4.53, 95% CI = [3.04–6.75] for EDSS ⩾6), and anti-CD20 therapies (OR = 2.67, 95% CI = [1.85–3.87]) as risk factors for COVID-19 severity. Vaccinated individuals experienced less severe COVID-19, whether on (risk ratio (RR) = 0.64, 95% CI = [0.60–0.69]) or off (RR = 0.32, 95% CI = [0.30–0.33]) anti-CD20. Discussion: In pwMS, consistent risk factors were anti-CD20 therapies and neurological disability, emerging as vital drivers of COVID-19 severity regardless of wave, period, or vaccination status.

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/13524585231218149

Reference32 articles.

1. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis

2. COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response

3. Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies

4. COVID-19 Severity in Multiple Sclerosis

5. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies